- Home
- PATH vs MDGL Comparison
PATH vs MDGL Comparison
Compare PATH & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PATH
- MDGL
- Stock Information
- Founded
- PATH 2005
- MDGL 2011
- Country
- PATH United States
- MDGL United States
- Employees
- PATH N/A
- MDGL N/A
- Industry
- PATH Computer Software: Prepackaged Software
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- PATH Technology
- MDGL Health Care
- Exchange
- PATH Nasdaq
- MDGL Nasdaq
- Market Cap
- PATH 6.0B
- MDGL 6.8B
- IPO Year
- PATH 2021
- MDGL N/A
- Fundamental
- Price
- PATH $12.49
- MDGL $294.64
- Analyst Decision
- PATH Hold
- MDGL Strong Buy
- Analyst Count
- PATH 20
- MDGL 10
- Target Price
- PATH $12.91
- MDGL $420.63
- AVG Volume (30 Days)
- PATH 12.4M
- MDGL 373.7K
- Earning Date
- PATH 05-29-2025
- MDGL 05-01-2025
- Dividend Yield
- PATH N/A
- MDGL N/A
- EPS Growth
- PATH N/A
- MDGL N/A
- EPS
- PATH N/A
- MDGL N/A
- Revenue
- PATH $1,429,664,000.00
- MDGL $317,383,000.00
- Revenue This Year
- PATH $8.91
- MDGL $230.69
- Revenue Next Year
- PATH $8.99
- MDGL $74.76
- P/E Ratio
- PATH N/A
- MDGL N/A
- Revenue Growth
- PATH 9.30
- MDGL N/A
- 52 Week Low
- PATH $9.38
- MDGL $200.08
- 52 Week High
- PATH $20.95
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- PATH 66.90
- MDGL 39.29
- Support Level
- PATH $11.63
- MDGL $287.46
- Resistance Level
- PATH $12.12
- MDGL $349.00
- Average True Range (ATR)
- PATH 0.35
- MDGL 17.20
- MACD
- PATH 0.15
- MDGL -2.36
- Stochastic Oscillator
- PATH 95.53
- MDGL 11.67
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.